Empazin
Generic Name
empazin-25-mg-tablet
Manufacturer
Generic Pharmaceutical Company
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| empazin 25 mg tablet | ৳ 30.00 | ৳ 300.00 |
Description
Overview of the medicine
Empazin 25 mg Tablet contains Empagliflozin, an SGLT2 inhibitor, used to lower blood sugar in adults with type 2 diabetes. It also reduces the risk of cardiovascular death, heart failure hospitalization, and kidney disease progression in certain patients.
Uses & Indications
Dosage
Adults
The recommended starting dose is 10 mg once daily in the morning, taken with or without food. If additional glycemic control is needed, the dose can be increased to 25 mg once daily.
Elderly
No dose adjustment is recommended based on age alone. However, renal function should be assessed before initiating and periodically during treatment.
Renal_impairment
Not recommended to initiate if eGFR is <30 mL/min/1.73 m². For patients with eGFR ≥30 mL/min/1.73 m², the dose can be continued at 10 mg or 25 mg once daily. Close monitoring is advised.
How to Take
Take Empazin 25 mg Tablet orally once daily in the morning, with or without food. Swallow the tablet whole with water. Do not crush, cut, or chew the tablet.
Mechanism of Action
Empagliflozin works by inhibiting the sodium-glucose co-transporter 2 (SGLT2) in the kidneys. This reduces the reabsorption of glucose from the filtered blood back into the bloodstream, leading to increased urinary glucose excretion and thus lowering blood glucose levels.
Pharmacokinetics
Onset
Within 30-60 minutes.
Excretion
Approximately 50% renally excreted as unchanged drug and metabolites; approximately 50% excreted via feces.
Half life
Approximately 12.4 hours.
Absorption
Rapidly absorbed after oral administration, with peak plasma concentrations reached 1.5 hours post-dose.
Metabolism
Primarily metabolized via glucuronidation by UGT1A3, UGT1A8, UGT1A9, and UGT2B7.
Side Effects
Contraindications
- •Hypersensitivity to empagliflozin or any excipients.
- •Patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), end-stage renal disease, or on dialysis.
- •Diabetic ketoacidosis.
Drug Interactions
Lithium
SGLT2 inhibitors may decrease lithium levels by increasing renal excretion. Monitor lithium levels.
Diuretics
May increase the risk of dehydration and hypotension. Close monitoring is advised.
Rifampicin
May decrease exposure to empagliflozin. Dose adjustment may be necessary if co-administered.
Insulin and Insulin Secretagogues
May increase the risk of hypoglycemia. A lower dose of insulin or secretagogue may be required.
Storage
Store below 30°C in a dry place, away from direct light and moisture. Keep out of reach of children.
Overdose
In the event of an overdose, symptomatic treatment and supportive measures should be initiated. Empagliflozin is not expected to be dialyzable.
Pregnancy & Lactation
Not recommended during the second and third trimesters of pregnancy due to potential fetal renal dysfunction. Use during lactation is not recommended as it is unknown if empagliflozin is excreted in human milk.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Usually 24 to 36 months from the date of manufacture.
Availability
Available in pharmacies, hospitals, and medical clinics
Approval Status
Approved by FDA and DGDA
Patent Status
Patented (active ingredient), generic versions may exist post-patent
WHO Essential Medicine
YesAlternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
